EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of delisting melatonin from a health-system formulary on psychotropic utilization

Ryan R D Chan iD, Tony Nickonchuk, Rekha Jabbal, Wilson Cheng, Micheal Guirguis

Australasian Psychiatry · 28.04.2026

DOI: 10.1177/10398562261446491 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Australasian Psychiatry, online erschienen am 28.04.2026. Verfasst von Ryan R D Chan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Alberta Health Services, Edmonton, AB, Canada. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To characterize the trends of psychotropic utilization before and after the formulary removal of melatonin in Alberta, Canada.

Methods

We conducted a retrospective drug utilization review of patients admitted to inpatient, long-term care, and pediatric units who received psychotropics for insomnia treatment. Utilization patterns were compared between two periods; pre-removal: January to December 2023 and post-removal: October 2024 to March 2025. Data were analyzed using defined daily dose per 1000 patient-days (DDD/1000PD).

Results

A total of 101 pre-removal and 115 post-removal sites were included. There was a 13.5% relative decrease in psychotropic use, from 731.83 to 632.78 DDD/1000PD. Melatonin use decreased from 95.60 to 13.94 DDD/1000PD. In the post-removal period, the psychotropic classes with the highest utilization rates were benzodiazepines (203.26 DDD/1000PD), Z-drugs (167.78 DDD/1000PD), and antidepressants (148.75 DDD/1000PD). The overall use of antidepressants increased by 17.3% while Z-drugs and benzodiazepines decreased by 8.8% and 8.4%, respectively.

Conclusions

The temporal trends of psychotropics varied among zones, sites, and years within the same site. Overall, there was a decrease in psychotropic utilization, largely driven by decreases in the use of Z-drugs and benzodiazepines. The findings should be interpreted with caution, as results may not be generalizable to other institutions.

Schlagwörter

Stichwörter der Autor:innen

drug utilizationformularyhealth-systemmelatoninpsychotropics

Autor:innen und Institutionen

  • Alberta Health Services, Edmonton, AB, Canada.
  • Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada.
  • Alberta Health Services, Peace River, AB, Canada.
  • Alberta Health Services, Calgary, AB, Canada.

ORCID-Profile: Ryan R D Chan

Zitieren

APA

Chan, R. R. D., Nickonchuk, T., Jabbal, R., Cheng, W., & Guirguis, M. (2026). Impact of delisting melatonin from a health-system formulary on psychotropic utilization. Australasian Psychiatry. https://doi.org/10.1177/10398562261446491

Vancouver

Chan RRD, Nickonchuk T, Jabbal R, Cheng W, Guirguis M. Impact of delisting melatonin from a health-system formulary on psychotropic utilization. Australasian Psychiatry. 2026. doi:10.1177/10398562261446491

BibTeX
@article{Chan2026,
  author = {Chan, Ryan R D and Nickonchuk, Tony and Jabbal, Rekha and Cheng, Wilson and Guirguis, Micheal},
  title = {Impact of delisting melatonin from a health-system formulary on psychotropic utilization},
  journal = {Australasian Psychiatry},
  year = {2026},
  doi = {10.1177/10398562261446491}
}
Kostenlos starten →